Recent studies have the efficacy of RMP1-14, a newly created anti-mouse PD-1 reagent , for improving malignant immunotherapy . Unlike existing approaches, RMP1-14 exhibits enhanced interaction to murine https://heathyqiu094955.wikicorrespondence.com/6624207/employing_this_a_new_murine_programmed_death_1_agent_in_immune_therapy